Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat

Environmental Health and Preventive Medicine

Volumn 17, Issue 6, 2012, Pages 444-456

  Moriya, Takashi ^a   Kitamori, Kazuya ^b   Naito, Hisao ^a   Yanagiba, Yukie ^a,c   Ito, Yuki ^a,d   Yamagishi, Nozomi ^a   Tamada, Hazuki ^a,b   Jia, Xiaofang ^a   Tsuchikura, Satoru ^e   Ikeda, Katsumi ^f   Yamori, Yukio ^f   Nakajima, Tamie ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINJO GAKUIN UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF OCCUPATIONAL SAFETY AND HEALTH   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e Disease Model Cooperative Research Association   (Japan)

^f MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Fibrosis; Inflammation; NF jb; Steatohepatitis; TNF a

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; COLLAGEN TYPE 1; COPPER ZINC SUPEROXIDE DISMUTASE; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; FAT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; PROTEIN P50; SYNAPTOTAGMIN I; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; HIGH CHOLESTEROL DIET INDUCED STEATOHEPATITIS; HIGH FAT DIET INDUCED STEATOHEPATITIS; INFLAMMATION; LIVER FIBROSIS; LIVER HOMOGENATE; MALE; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CHOLESTEROL; CHOLESTEROL, DIETARY; DIET, HIGH-FAT; DIETARY FATS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER CIRRHOSIS; MALE; PPAR ALPHA; RATS; RATS, INBRED SHR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

RATTUS;

EID: 84869502178     PISSN: 1342078X     EISSN: 13474715     Source Type: Journal    
DOI: 10.1007/s12199-012-0273-y     Document Type: Article

References (54)

1. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine- adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006;131:934-45.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.
3. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol. 2011;46(Suppl 1):63-9.
4. Powell EE, Jonsson JR, Clouston AD. Dangerous liaisons: the metabolic syndrome and nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:753-4.
5. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol. 2008;23:1635-48.
6. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator- activated receptor-a and -3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol. 2006;169:846-60.
7. Yamori Y. Selection of arteriolipidosis-prone rats (ALR). Jpn Heart J. 1977;18:602-3.
8. Kitamori K, Naito H, Tamada H, Kobayashi M, Miyazawa D, Yasui Y, et al. Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. Environ Health Prev Med. doi: 10.1007/s12199-011-0235-9
9. Sansawa H, Takahashi M, Tsuchikura S, Endo H. Effect of chlorella and its fractions on blood pressure, cerebral stroke lesions, and life-span in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo). 2006;52:457-66.
10. Folch J, Lees M. Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497-509.
11. Ito Y, Yamanoshita O, Asaeda N, Tagawa Y, Lee CH, Aoyama T, et al. Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor a-independent pathway. J Occup Health. 2007;49:172-82.
12. Ramdhan DH, Kamijima M, Yamada N, Ito Y, Yanagiba Y, Nakamura D, et al. Molecular mechanism of trichloroethyleneinduced hepatotoxicity mediated by CYP2E1. Toxicol Appl Pharmacol. 2008;231:300-7.
13. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, et al. Altered constitutive expression of fatty acidmetabolizing enzymes in mice lacking the peroxisome proliferator- activated receptor alpha (PPARa). J Biol Chem. 1998;273: 5678-84.
14. Okiyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ, et al. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARa-null mice through attenuation of increases in oxidative stress. J Hepatol. 2009;50:1236-46.
15. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull. 1945;1:80-3.
16. Bauer DF. Constructing confidence sets using rank statistics. J Am Stat Assoc. 1972;67:687-90.
17. Yoo HY, Chang MS, Rho HM. Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferatorresponsive element by arachidonic acid. Gene. 1999;234:87-91.
18. Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov. 2004;3:340-51.
19. Long YC, Zierath Jr. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest. 2006;116:1776-83.
20. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13:332-9.
21. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor a target genes. Cell Mol Life Sci. 2004;61: 393-416.
22. Yamazaki T, Sasaki E, Kakinuma C, Yano T, Miura S, Ezaki O. Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1. J Biol Chem. 2005;280:21506-14.
23. Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem. 2001;276:38870-6.
24. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366-74.
25. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125-72.
26. Day CP, James OF. Steatohepatitis: a tale of two ''hits''? Gastroenterology. 1998;114:842-5.
27. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 2010;55:560-78.
28. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001;34:1158-63.
29. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-112.
30. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-a function. Nature. 1997;389:610-4.
31. Fu JH, Xie SR, Kong SJ, Wang Y, Wei W, Shan Y, et al. The combination of a high-fat diet and chronic stress aggravates insulin resistance in Wistar male rats. Exp Clin Endocrinol Diabetes. 2009;117:354-60.
32. Romestaing C, Piquet MA, Bedu E, Rouleau V, Dautresme M, Hourmand-Ollivier I, et al. Long term highly saturated fat diet does not induce NASH in Wistar rats. Nutr Metab (Lond). 2007;4:4.
33. Plumpe J, Malek NP, Bock CT, Rakemann T, Manns MP, Trautwein C. NF-jB determines between apoptosis and proliferation in hepatocytes during liver regeneration. Am J Physiol Gastrointest Liver Physiol. 2000;278:G173-83.
34. Chakraborty JB, Mann DA. NF-jB signalling: embracing complexity to achieve translation. J Hepatol. 2010;52:285-91.
35. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor a negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-jB and AP-1. J Biol Chem. 1999;274:32048-54.
36. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IjBa expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-a activators. J Biol Chem. 2000;275:36703-7.
37. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-c is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
38. Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, et al. Peroxisome proliferator-activated receptor a protects against alcohol-induced liver damage. Hepatology. 2004;40:972-80.
39. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARc ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094-9.
40. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8:731-7.
41. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-a or adiponectin? Hepatology. 2004;40:46-54.
42. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247-50.
43. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol. 2003;38[Suppl 1]:S38-53.
44. Vergnes L, Phan J, Strauss M, Tafuri S, Reue K. Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J Biol Chem. 2003;278:42774-84.
45. Breitkopf K, Roeyen C, Sawitza I, Wickert L, Floege J, Gressner AM. Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors a and b in activated rat hepatic stellate cells (HSC). Cytokine. 2005;31:349-57.
46. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, et al. Liver peroxisome proliferator-activated receptor c contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003;278:34268-76.
47. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-95.
48. Tomita K, Azuma T, Kitamura N, Nishida J, Tamiya G, Oka A, et al. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology. 2004;126: 873-85.
49. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-307.
50. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:909-16.
51. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106-10.
52. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990;85:1349-55.
53. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology. 2010;51:1979-87.
54. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26[Suppl 1]:163-72.